190 related articles for article (PubMed ID: 30645823)
1. ibrutinib (IMBRUVICA°) and Waldenström's macroglobulinaemia.
Prescrire Int; 2016 Oct; 25(175):232. PubMed ID: 30645823
[TBL] [Abstract][Full Text] [Related]
2. Sudden ventricular fibrillation and death during ibrutinib therapy-A case report.
Bernardeschi P; Pirrotta MT; Del Rosso A; Fontanelli G; Milandri C
Eur J Haematol; 2019 Oct; 103(4):442-443. PubMed ID: 31287200
[TBL] [Abstract][Full Text] [Related]
3. Ibrutinib in previously treated Waldenström's macroglobulinemia.
Treon SP; Tripsas CK; Meid K; Warren D; Varma G; Green R; Argyropoulos KV; Yang G; Cao Y; Xu L; Patterson CJ; Rodig S; Zehnder JL; Aster JC; Harris NL; Kanan S; Ghobrial I; Castillo JJ; Laubach JP; Hunter ZR; Salman Z; Li J; Cheng M; Clow F; Graef T; Palomba ML; Advani RH
N Engl J Med; 2015 Apr; 372(15):1430-40. PubMed ID: 25853747
[TBL] [Abstract][Full Text] [Related]
4. Ibrutinib monotherapy outside of clinical trial setting in Waldenström macroglobulinaemia: practice patterns, toxicities and outcomes.
Abeykoon JP; Zanwar S; Ansell SM; Gertz MA; Kumar S; Manske M; Novak AJ; King R; Greipp P; Go R; Inwards D; Muchtar E; Habermann T; Witzig TE; Thompson CA; Dingli D; Lacy MQ; Leung N; Dispenzieri A; Gonsalves W; Warsame R; Kyle RA; Rajkumar V; Parikh SA; Kapoor P
Br J Haematol; 2020 Feb; 188(3):394-403. PubMed ID: 31468508
[TBL] [Abstract][Full Text] [Related]
5. Resolution of Waldenström Macroglobulinemia-Associated Autoimmune Hemolysis With Ibrutinib.
Tripathi A; Steingart R
J Oncol Pract; 2016 May; 12(5):490-1. PubMed ID: 27170696
[No Abstract] [Full Text] [Related]
6. Ibrutinib in pretreated Waldenström's macroglobulinaemia.
Bagcchi S
Lancet Oncol; 2015 May; 16(5):e204. PubMed ID: 25892147
[No Abstract] [Full Text] [Related]
7. Ibrutinib-induced acute liver failure.
Kahn A; Horsley-Silva JL; Lam-Himlin DM; Reeder CB; Douglas DD; Carey EJ
Leuk Lymphoma; 2018 Feb; 59(2):512-514. PubMed ID: 28693376
[No Abstract] [Full Text] [Related]
8. [Ibrutinib prescription in B-cell lymphoid neoplasms].
Dougé A; Ravinet A; Bay JO; Tournilhac O; Guièze R; Lemal R
Bull Cancer; 2016 Feb; 103(2):127-37. PubMed ID: 26822906
[TBL] [Abstract][Full Text] [Related]
9. Zanubrutinib for the treatment of Waldenström Macroglobulinemia.
Lim KJC; Tam CS
Expert Rev Hematol; 2020 Dec; 13(12):1303-1310. PubMed ID: 33297772
[No Abstract] [Full Text] [Related]
10. Rituximab and ibrutinib in the treatment of Waldenström's macroglobulinemia.
Grunenberg A; Buske C
Future Oncol; 2019 Aug; 15(23):2687-2697. PubMed ID: 31184501
[TBL] [Abstract][Full Text] [Related]
11. Ibrutinib discontinuation in Waldenström macroglobulinemia: Etiologies, outcomes, and IgM rebound.
Gustine JN; Meid K; Dubeau T; Severns P; Hunter ZR; Guang Y; Xu L; Treon SP; Castillo JJ
Am J Hematol; 2018 Aug; 93(4):511-517. PubMed ID: 29280186
[TBL] [Abstract][Full Text] [Related]
12. Ibrutinib in the management of Waldenstrom macroglobulinemia.
Yosef A; Touloukian EZ; Nambudiri VE
J Oncol Pharm Pract; 2019 Mar; 25(2):434-441. PubMed ID: 29996737
[TBL] [Abstract][Full Text] [Related]
13. Ibrutinib for patients with rituximab-refractory Waldenström's macroglobulinaemia (iNNOVATE): an open-label substudy of an international, multicentre, phase 3 trial.
Dimopoulos MA; Trotman J; Tedeschi A; Matous JV; Macdonald D; Tam C; Tournilhac O; Ma S; Oriol A; Heffner LT; Shustik C; García-Sanz R; Cornell RF; de Larrea CF; Castillo JJ; Granell M; Kyrtsonis MC; Leblond V; Symeonidis A; Kastritis E; Singh P; Li J; Graef T; Bilotti E; Treon S; Buske C;
Lancet Oncol; 2017 Feb; 18(2):241-250. PubMed ID: 27956157
[TBL] [Abstract][Full Text] [Related]
14. Dose of ibrutinib in Waldenström macroglobulinaemia: Less can be more.
Tohidi-Esfahani I; Trotman J
Br J Haematol; 2023 Jun; 201(5):807-808. PubMed ID: 36715656
[TBL] [Abstract][Full Text] [Related]
15. Low risk of Pneumocystis jirovecii pneumonia and invasive aspergillosis in patients with Waldenström macroglobulinaemia on ibrutinib.
Cheng MP; Kusztos AE; Gustine JN; Dryden-Peterson SL; Dubeau TE; Woolley AE; Hammond SP; Baden LR; Treon SP; Castillo JJ; Issa NC
Br J Haematol; 2019 May; 185(4):788-790. PubMed ID: 30460682
[No Abstract] [Full Text] [Related]
16. An evaluation of Ibrutinib for the treatment of Waldenstrom macroglobulinaemia.
Lim KJC; Tam CS
Expert Opin Pharmacother; 2020 Sep; 21(13):1555-1564. PubMed ID: 32603202
[TBL] [Abstract][Full Text] [Related]
17. Ibrutinib (Imbruvica) for chronic lymphocytic leukemia.
Med Lett Drugs Ther; 2014 Apr; 56(1440):29-30. PubMed ID: 24736247
[No Abstract] [Full Text] [Related]
18. CXCL13 levels are elevated in patients with Waldenström macroglobulinemia, and are predictive of major response to ibrutinib.
Vos JM; Tsakmaklis N; Patterson CJ; Meid K; Castillo JJ; Brodsky P; Ganz T; Pals ST; Kersten MJ; Xu L; Yang G; Treon SP; Hunter ZR
Haematologica; 2017 Nov; 102(11):e452-e455. PubMed ID: 28798070
[No Abstract] [Full Text] [Related]
19. Ibrutinib in B lymphoid malignancies.
Smith MR
Expert Opin Pharmacother; 2015; 16(12):1879-87. PubMed ID: 26165513
[TBL] [Abstract][Full Text] [Related]
20. MYD88 Mutations and Response to Ibrutinib in Waldenström's Macroglobulinemia.
Treon SP; Xu L; Hunter Z
N Engl J Med; 2015 Aug; 373(6):584-6. PubMed ID: 26244327
[No Abstract] [Full Text] [Related]
[Next] [New Search]
